clinical resistance sti cancer therapy caused bcr-abl gene mutation amplification
clinical studies tyrosine kinase inhibitor sti chronic myeloid leukemia demonstrate many patients advanced stage disease respond initially relapse biochemical molecular analysis clinical material find drug resistance associated reactivation bcr-abl signal transduction cases examined six nine patients resistance associated single amino acid substitution threonine residue kinase domain known form critical hydrogen bond drug substitution threonine isoleucine sufficient confer sti resistance reconstitution experiment three patients resistance associated progressive bcr-abl gene amplification studies provide evidence genetically complex cancers retain dependence initial oncogenic event suggest strategy identifying inhibitors sti resistance
